StockData

Protagonist Therapeutics vs Ultragenyx Pharmaceutical

PTGX and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PTGX and RARE compare

Protagonist Therapeutics is the larger company, worth 5.2 times as much as Ultragenyx Pharmaceutical ($8.1B against $1.6B).

Protagonist Therapeutics grew revenue faster over the last twelve months (34.8% versus 17.5% for Ultragenyx Pharmaceutical).

Protagonist Therapeutics keeps more of each dollar of sales as profit, with a net margin of 29.4% compared with −81.7% at Ultragenyx Pharmaceutical.

Protagonist Therapeutics scores higher on the StockData Score (12 against 9 for Ultragenyx Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPTGXRARE
Size and price
Market cap$8.1B$1.6B
Share price$124.83$15.90
Change, 1 year50.0%−51.7%
Change, 5 years275%−79.2%
Beta (5Y)0.592.20
Employees1321,371
StockData Score
Total score12 (better)9
Valuation score01 (better)
Growth score22
Performance score4 (better)1
Health score6 (better)5
Dividend score00
Valuation
P/E121×–
P/S28.6×2.2× (better)
P/B9.6×–
EV/EBITDA122×–
P/FCF61.9×–
FCF yield1.6% (better)−31.2%
Fair value$41.72–
Margin of safety−199%–
Growth
Revenue growth (TTM)34.8% (better)17.5%
Revenue growth, 5Y average10.0%19.9% (better)
Net income growth (TTM)59.3%–
EPS growth (TTM)47.1%–
Profitability
Operating margin20.7% (better)−73.6%
Net margin29.4% (better)−81.7%
FCF margin46.3% (better)−68.2%
Return on equity11.0%–
Return on invested capital73.3%–
Financial health
Debt / equity0.00–
Current ratio21.71 (better)1.73
Altman Z-score111.24 (better)−5.29
Piotroski F-score55
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions117%108%
Held by insiders1.7%4.0%
Insider net buying, 12 months−$95.0M−$3.8M (better)
Superinvestors holding1–
Short interest, % of float16.1%25.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.